
News
Moderna, Pfizer, and Novavax's stock prices surged sharply as the FDA approved COVID-19 vaccinations for high-risk populations

Moderna, Pfizer, and Novavax's stock prices surged sharply as the FDA approved COVID-19 vaccinations for high-risk populations